A veterinarian who owns a three-doctor general practice in a good suburban market had her best year in 2025. Collections came in at $2.9 million, adjusted EBITDA at $520,000, and she personally produced just under two thirds of it, the surgical caseload, the dental work, the complex medicine, the clients who ask for her by name. She reads that production as the practice's engine, because it is. When she took the practice to market this spring expecting the multiples she had read about, the first indications arrived at a level she thought was reserved for practices half her size. Her financials were clean. Nothing in them was disputed. The number that set her multiple appears nowhere in them: the share of the practice that is her.
The practice's best line and its biggest risk are the same line, and the line is the owner.
A buyer prices what transfers
The cause is structural. A practice's earnings blend two components the P&L never separates. One part is produced by the system: the associates, the technicians, the protocols, the recurring wellness revenue, the client base attached to the building. The other part is produced by the owner personally, by her hands and her relationships. The blended EBITDA reports the two as one number. A buyer separates them, because only one of the two is for sale. The owner's production sits in the trailing twelve months, and in three years it will be wherever the owner is. A buyer prices the future cash flow that survives the transfer, and cash flow produced by the seller's own hands survives only if it can be replaced.
The market prices this separation openly. Published 2026 veterinary transaction guides put associate-driven general practices at 9 to 13 times adjusted EBITDA and owner-dependent practices at 4 to 7, and the sector literature treats owner clinical share as the single largest multiple driver in veterinary M&A, ahead of size, geography, and payer dynamics. Practices with owner production above 70 percent are observed at the bottom of the band for their size. Valuation practitioners put the provider concentration discount at 20 to 30 percent on its own. The discount arrives before negotiation begins. It is built into the band the buyer selects on day one.
Same EBITDA, different money
Two three-doctor general practices in comparable markets, each collecting $2.9 million, each showing $520,000 in adjusted EBITDA. On the financials, the same practice twice.
In the first, the owner produces 30 percent of collections. Two seasoned associates carry the rest on signed agreements, the surgical schedule is distributed, wellness plan revenue recurs monthly, and the busiest clients have relationships with the practice, because the practice made sure of it. A consolidator's indication arrives at 8 times: $4.16 million, with a standard one-year clinical transition for the seller.
In the second, the owner produces 65 percent. The associates handle wellness and routine medicine while she performs all the surgery and dentistry, and the referring clinics in the area send cases to her, by name. The indication arrives at 5.5 times: $2.86 million, conditioned on a 24-month post-close employment commitment, because the buyer's model treats her exit as the loss of $1.9 million in annual production. Replacing that production means recruiting roughly two full-time doctors in a market where associate compensation averages about $130,000 and runs to $165,000 before benefits and signing incentives, and where, per AVMA and industry workforce reporting, associate seats are the hardest roles in the profession to fill and stay open the longest. The buyer prices the cost of that replacement and the odds of achieving it, and both go into the multiple.
Same collections, same EBITDA, $1.3 million apart before a single term is negotiated. The gap is the discount, and it was set by a number neither practice reports.
Three forces, each deeper than the last
The first force is concentration itself. The revenue is real, but ownership of it is split. Revenue produced by the system belongs to the practice and transfers with the keys. Revenue produced by the owner belongs, in the economic sense that matters to a buyer, to the owner, and the sale of the practice does not include her. The higher her share, the smaller the business actually on the table, whatever the top line says.
The second force is replacement scarcity, and it is what converts a staffing question into a valuation event. If replacement doctors were abundant, owner production would be a line-item cost, the market wage times the hours. They are not abundant. The profession's workforce gap is structural, demand for clinical capacity is growing faster than the supply of doctors, and the major consolidators are competing for the same associates every independent practice is trying to hire. So the buyer prices two things: the full market cost of the replacement, and the risk that the search takes eighteen months or fails. Scarcity moves the discount from the cost of a salary to the price of an uncertainty, and the buyer holds the pen on pricing it.
The third force is attachment, and it is the one no hire can fix. Veterinary medicine is relationship medicine. A meaningful share of an owner-dependent practice's goodwill is personal: clients bonded to the doctor, referral flows aimed at her name. Personal goodwill transfers only by handoff, slowly, doctor to doctor, visit by visit, which is exactly why buyers of owner-dependent practices require the 12 to 24 month retention periods that sector advisors describe as the standard structure for narrowing the discount. The owner's excellence built value the practice cannot own. That is the deepest version of the problem, and it is also the reason the discount feels so unjust to the owner: the thing being discounted is the thing she is best at.
The number the practice cannot report
The measurement is transferable EBITDA: the earnings that survive the owner's exit. Compute it directly. Take the owner's clinical production and replace it at the full market cost of the doctors required to produce it, compensation, benefits, recruiting, and ramp time included. Then haircut the revenue attached personally to the owner, the ask-for-her clients and the name-directed referrals, by an honest transition attrition rate. What remains is the practice a buyer is actually pricing. The spread between book EBITDA and transferable EBITDA is the dependency discount, and it is computable years before any buyer exists. No practice management report will ever produce it, because every report the practice runs measures production, and production is precisely the number that conflates the system with the owner.
Run the spread and the owner's question changes. What the practice is worth turns out to be the wrong question, because there are two practices in the building, and only one of them is for sale. The governing question is how much of the practice leaves when the owner does, and that question rewards early answers. The dependency deepens by default: the owner keeps the surgeries because she is fastest, keeps the top clients because they ask, and every year of that concentrates the practice further into her hands. Closing the spread takes years, not months. A doctor has to be recruited in a scarce market, seasoned, and handed relationships visit by visit, and a buyer wants to see the new distribution hold in the trailing numbers before pricing it. The owner who starts three years out sells the practice. The owner who starts at the sale sells herself, on a two-year employment agreement, at a discount.
What she built and what she can sell
The owner built the practice by being the best doctor in it, and the buyer discounts the practice for the same reason. Both are correct. The production that built the practice is the one asset inside it the owner cannot sell, and the work of a transition is moving as much of it as possible into hands that stay.
This essay describes general transaction structure. It is general in nature and does not constitute legal advice, a valuation, or investment advice. Figures drawn from published sources are attributed in the text; case figures are illustrative composites and describe no identifiable practice.
Sources. Ackerman Group, quarterly veterinary market updates, 2025 through Q1 2026. Provident Healthcare Partners, veterinary sector commentary. AVMA workforce and practice data, 2025 through 2026. VHMA compensation and staffing benchmarks. SovDoc 2025 and published 2026 veterinary transaction guides (DVMElite, Transitions Elite, RightFit Capital) on multiple ranges and owner-dependency effects. ZipRecruiter national associate veterinarian compensation data, May 2026. Industry workforce reporting on the structural DVM shortage, 2025 through 2026.
← More from The Decision Layer